Anhui Shanhe Pharmaceutical Excipients Co.Ltd(300452) ( Anhui Shanhe Pharmaceutical Excipients Co.Ltd(300452) ) in 2021, it continued to expand cooperation with well-known Chinese pharmaceutical enterprises, achieved phased results in national generic drug consistency evaluation and volume procurement, and made significant progress in import substitution projects, mainly replacing 25 import customers, exceeding the plan at the beginning of the year.
According to the data, the company’s consolidated statements achieved an operating revenue of 617 million yuan, an increase rate of 16.1%, and a net profit attributable to shareholders of listed companies of 892533 million yuan, a year-on-year decrease of 4.99%. In 2021, the profit growth rate of Anhui Shanhe Pharmaceutical Excipients Co.Ltd(300452) slowed down. The main reason is that the prices of wood pulp, corn starch, propylene oxide, stearic acid and other raw materials have increased greatly, the cost of foreign trade export has increased, and the goodwill impairment of subsidiaries has been accrued. At the same time, Qufu Tianli, a holding subsidiary, has a relatively single product structure and fierce market competition. The sharp rise in the price of main raw materials has put great pressure on its operating performance. In 2021, it achieved an operating revenue of 1003138 million yuan, an increase of 6.2% over the previous year, and a net profit of -6.7882 million yuan, a decrease of 6.3155 million yuan over the previous year.
During the reporting period, Anhui Shanhe Pharmaceutical Excipients Co.Ltd(300452) applied for 2 invention patents. At present, there are 16 national invention patents, and another 6 invention patents are in the trial stage; Four new pharmaceutical excipients, including anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, calcium sulfate and microcrystalline cellulose sodium carboxymethylcellulose, have been added. At present, 34 products of the company have obtained CDE registration number, and the main products have been successfully associated with the preparation and are in the activated (a) state; Three new products including corn starch, sodium stearate fumarate and silicified microcrystalline cellulose were added, and the DMF (drug management archives) filing number of FDA was obtained; A total of 14 products of the company have obtained the US DMF filing number and 8 varieties have obtained the EU Express Certification.
According to the annual report, the construction of Anhui Shanhe Pharmaceutical Excipients Co.Ltd(300452) phase I project of “new pharmaceutical excipients production base” located in the pharmaceutical and chemical industry park of Huainan Economic and Technological Development Zone is continuing. After the completion of the project, 9000 tons of high-end excipients will be added. The project is currently in the early civil construction stage and is planned to be put into operation in 2023.
